{
  "docId": "019de073-bfd4-723b-805d-c3152d3a00ff",
  "docSlug": "7df1d9bdbc08777b7243fabbc766ed39",
  "documentTitle": "Immatics | Results Presentation Deck | 25 slides",
  "authorId": "immatics",
  "authorName": "Immatics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7860465,
  "pageNumber": 16,
  "pageCount": 25,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "dense",
  "nDataPoints": 48,
  "notes": "The table calculates the addressable patient population by filtering total incidence down to R/R incidence, then applying PRAME positivity and HLA-A*02:01+ prevalence.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-bfd4-723b-805d-c3152d3a00ff/16",
  "deckHref": "/decks/019de073-bfd4-723b-805d-c3152d3a00ff",
  "deckJsonHref": "/decks/019de073-bfd4-723b-805d-c3152d3a00ff.json",
  "deckAnchorHref": "/decks/019de073-bfd4-723b-805d-c3152d3a00ff#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.98,
        "x": 0.01,
        "y": 0.95
      },
      "kind": "disclaimer",
      "text": "Incidences based on public estimates and Immatics internal model; Relapsed/refractory (R/R) or last-line patient population approximated by annual mortality; Estimated 41% HLA-A*02:01 positive population in the US...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14df4ef2-7ef2-4b06-bb3f-4dc1835d36b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.65,
        "x": 0.04,
        "y": 0.72
      },
      "kind": "list",
      "text": "Multiple opportunities to broaden patient reach and patient benefit: Expand beyond US population; Expand into other indications; Move into earlier lines of therapy; Inclusion of patients with lower PRAME-threshold",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a418e900-f458-49d0-a414-79399eeb7849",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.75,
        "x": 0.22,
        "y": 0.21
      },
      "kind": "table",
      "text": "Table showing incidence, R/R incidence, PRAME positive %, and final patient population for 12 cancer indications.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c1b12d59-f342-4f74-a895-e1aa7e887d5e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.04,
        "y": 0.11
      },
      "kind": "title",
      "text": "~39,000 Patients per Year in the US only",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cf24645f-f921-46af-8a0a-0431788b72b5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.65,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "IMA203 TCR-T Has the Potential to Reach a Large Patient Population",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d0792fe-83e0-478c-86d7-6f11a33dfd55",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "9b889384-de0d-46d4-997b-683556f7bb0b",
      "evidence": "Table showing incidence, R/R incidence, PRAME positive %, and final patient population for 12 cancer indications.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "market-sizing",
      "slug": null,
      "matchId": "5e74ae97-1ba4-41df-9374-34571cabba42",
      "evidence": "The slide uses a funnel-like calculation (Incidence -> R/R -> PRAME+ -> HLA+) to estimate total addressable market.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 17,
      "from": 9,
      "beatId": "3c0d3c19-4cb2-45ea-940b-4a17ae6aecd2",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "Slides 9-17 present the interim clinical data and results of ACTengine IMA203.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 18,
      "from": 16,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "05862a2d-ddc7-4a3d-903b-2c79bb70aab4",
      "evidence": "Slides 16-18 discuss market potential and clinical benefit.",
      "position": 1,
      "objective": "Highlight potential for large patient population",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}